Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial

Lancet Infectious Diseases
Feb 2021 Volume 21 Number 2 p149-296, e16-e35
https://www.thelancet.com/journals/laninf/issue/current

 

Articles
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial
Yanjun Zhang, et al